Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.45 |
| ▸ | DBH | P09172 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31256667 | 1.00 | CA2 (0.59) | CA2HSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL71042 | 0.83 | HSD17B10 (0.63) | CA2HSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL9773533 | 0.83 | CA2 (0.61) | CA2HSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL5454185 | 0.82 | KDM4E (0.65) | CA2HSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL2982854 | 0.81 | TTR (0.53) | CA2HSD17B10TSHRCYP3A4TTR | |
| SCHEMBL1693883 | 0.81 | CA2 (0.59) | CA2HSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL92905 | 0.80 | IDO1 (0.58) | HSD17B10TSHRIGF1RALOX15RECQL | |
| SCHEMBL9745836 | 0.79 | IGF1R (0.66) | CA2HSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL6635358 | 0.79 | CA2 (0.57) | CA2HSD17B10TSHRCYP1A2CYP3A4 | |
| SCHEMBL5445840 | 0.79 | CA2 (0.57) | CA2HSD17B10TSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119032076-A | Novel compounds and uses thereof | 株式会社安提昂 | 2024-11-26 | — | — | CN | disclosed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-111954525-B | Prodrugs of fused bicyclic C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023239171-A1 | NOVEL COMPOUND AND USE THEREOF | 주식회사 엑티브온 | 2023-12-14 | — | — | WO | disclosed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115279359-A | Novel thyromimetic agents | 速通医疗公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3773563-A1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111954525-A | Prodrugs of fused bicyclic C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2019195159-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-5866700-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-02 | — | — | US | disclosed |
| US-5652358-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | disclosed |
| US-5463013-A | Transparency, heat resistance, dimensional stability, tracking resistance | TEIJIN CHEMICALS, LTD. (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | disclosed |
| EP-0622393-A2 | Modified aromatic polycarbonate resin and modified phenol for preparing it | Teijin Chemicals, Ltd. (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-4588835-A | Process for preparing alkoxyphenols | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1986-05-13 | — | — | US | disclosed |
| US-4525304-A | Process for preparing oxazolinoazetidinones | ELI LILLY AND COMPANY (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0109817-A2 | Process for preparing oxazolinoazetidinones | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| US-4119671-A | OXIDATION OF HYDROXYBENZYL ALCOHOLS, PLATINUM CATALYST, ACTIVATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-10 | — | — | US | disclosed |
| US-3951662-A | Method of antistatic treatment for silver halide photosensitive materials | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | CA2 1784/4885HSD17B10 3225/4885TSHR 384/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | CA2 1784/4885HSD17B10 3225/4885TSHR 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.